Earnings History Data for Seres Therapeutics (MCRB) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Seres Therapeutics

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-03-2024	PM		MCRB	Seres Therapeutics	166.00	-0.32	-0.40	0.00	Seres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23M [3/5/2024 7:03 AM]	1.06	-0.08 (-7.02%)	1.05	-0.09 (-7.89%)	0.91 - 6.87	4,866,482	3,820,000	1,677,437
Seres Therapeutics Q4 2023 Earnings Preview [3/4/2024 11:04 AM] Seres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23M [3/5/2024 7:03 AM]
02-11-2023	PM		MCRB	Seres Therapeutics, Inc.	196.15	-0.37	-0.47	-0.49	Seres Therapeutics GAAP EPS of -$0.37 beats by $0.13, revenue of $0.31M misses by $0.54M [11/2/2023 8:10 AM]	0.9324	-0.51 (-35.25%)	0.93	0.0 (-0.34%)	0.91 - 9.13	15,847,256	3,220,000	25,916
Seres Therapeutics GAAP EPS of -$0.37 beats by $0.13, revenue of $0.31M misses by $0.54M [11/2/2023 8:10 AM]
08-08-2023	PM		MCRB	Seres Therapeutics, Inc.	631.83	0.36	0.55	-0.70	Seres Therapeutics GAAP EPS of $0.36 misses by $0.17, revenue of $126.47M beats by $0.8M [8/8/2023 7:11 AM]	4.25	-0.36 (-7.81%)	4.80	0.19 (4.12%)	4.16 - 9.49	6,490,962	1,900,000	131,294
Seres Therapeutics Q2 2023 Earnings Preview [8/7/2023 3:44 PM] Seres Therapeutics GAAP EPS of $0.36 misses by $0.17, revenue of $126.47M beats by $0.8M [8/8/2023 7:11 AM]
09-05-2023	PM	7:00 AM ET (May 9)	MCRB	Seres Therapeutics, Inc.	755.47	-0.57	-0.57	-0.61	Seres Therapeutics GAAP EPS of -$0.57 misses by $0.02 [5/9/2023 7:04 AM]	5.56	0.0 (0.00%)	5.35	-0.21 (-3.78%)	2.50 - 9.49	3,425,468	7,100,000	123,125
Seres Therapeutics Q1 2023 Earnings Preview [5/8/2023 2:34 PM] Seres Therapeutics GAAP EPS of -$0.57 misses by $0.02 [5/9/2023 7:04 AM]
07-03-2023	PM	7:00 AM ET (Mar 7)	MCRB	Seres Therapeutics, Inc.	636.66	-0.54	-0.43	-0.55	Seres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62M [3/7/2023 7:01 AM]	5.42	-0.07 (-1.28%)	5.31	-0.18 (-3.27%)	2.50 - 9.49	1,610,875	780,000	6,460
Seres Therapeutics FY 2022 Earnings Preview [3/6/2023 11:14 AM] Seres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62M [3/7/2023 7:01 AM] Seres Therapeutics falls 9% on full-year earnings miss [3/7/2023 12:20 PM]
02-11-2022	PM	7:00 AM ET (Nov 2)	MCRB	Seres Therapeutics, Inc.	1,100	-0.49	-0.45	0.72	Seres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57M [11/2/2022 7:10 AM]	8.21	-0.85 (-9.34%)	8.59	-0.46 (-5.08%)	2.50 - 11.69	1,355,321	1,110,000	3,921
Seres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57M [11/2/2022 7:10 AM] Seres stock sinks as Q3 plunges in loss [11/2/2022 1:03 PM] Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates [Nov-02-22 07:00AM]
03-08-2022	PM	7:00 AM ET (Aug 3)	MCRB	Seres Therapeutics, Inc.	336.64	-0.70	-0.58	-0.53	Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M [8/3/2022 7:11 AM]	4.45	0.35 (8.41%)	4.13	0.03 (0.73%)	2.50 - 11.69	1,453,282	1,320,000	9,468
Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M [8/3/2022 7:11 AM] Seres rises 16% as co expects to file BLA for C. difficile infection treatment in coming weeks [8/3/2022 10:42 AM] Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates [Aug-03-22 07:00AM]
04-05-2022	PM	7:00 AM ET (May 4)	MCRB	Seres Therapeutics	435.00	-0.61	-0.56	0.00	Seres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49M [5/4/2022 7:11 AM]	4.71	-0.13 (-2.74%)	4.85	0.01 (0.21%)	4.30 - 25.05	538,845	630,000	419
Seres Therapeutics Q1 2022 Earnings Preview [5/3/2022 11:03 AM] Seres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49M [5/4/2022 7:11 AM] Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates [May-04-22 07:00AM] Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates [May-04-22 08:25AM]
01-03-2022	PM	7:00 AM ET (Mar 1)	MCRB	Seres Therapeutics, Inc.	757.74	-0.55	-0.45	-0.18	Seres Therapeutics GAAP EPS of -$0.72 misses by $0.10, revenue of $144.92M misses by $4.9M [3/1/2022 7:13 AM]	7.38	-0.61 (-7.69%)	7.77	-0.23 (-2.88%)	5.41 - 25.05	929,625	710,000	301
Seres Therapeutics GAAP EPS of -$0.72 misses by $0.10, revenue of $144.92M misses by $4.9M [3/1/2022 7:13 AM] Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates [Feb-28-22 05:35PM] Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs [Feb-28-22 09:00AM] Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates [Mar-01-22 07:00AM] Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates [Mar-01-22 09:05AM]
10-11-2021	PM	7:00 AM ET (Nov 10)	MCRB	Seres Therapeutics, Inc.	640.20	0.72	-0.47	-0.36	Seres Therapeutics EPS beats by $0.75, beats on revenue [11/10/2021 7:18 AM]	8.28	1.41 (20.52%)	7.30	0.43 (6.26%)	5.41 - 38.50	11,011,044	1,190,000	12,244
Seres Therapeutics Q3 2021 Earnings Preview [11/9/2021 11:45 AM] Seres Therapeutics EPS beats by $0.75, beats on revenue [11/10/2021 7:18 AM] Seres Therapeutics and Bacthera ink collaboration agreement [11/10/2021 7:40 AM] Seres Therapeutics shares surge 30% after Q3 earnings beat [11/10/2021 12:09 PM] Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection [Nov-10-21 02:00AM] Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates [Nov-10-21 07:00AM] Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates [Nov-10-21 08:15AM] Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday [Nov-10-21 04:14PM]
03-08-2021	PM	7:00 AM ET (Aug 3)	MCRB	Seres Therapeutics, Inc.	650.91	-0.53	-0.41	-0.28	Seres Therapeutics EPS misses by $0.16, misses on revenue [8/3/2021 7:07 AM]	6.94	-0.09 (-1.28%)	6.96	-0.07 (-1.00%)	3.84 - 38.50	1,717,195	4,050,000	6,422
Seres Therapeutics EPS misses by $0.16, misses on revenue [8/3/2021 7:07 AM] Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates [Aug-03-21 07:00AM] Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates [Aug-03-21 08:45AM]
04-05-2021	PM	7:00 AM ET (May 4)	MCRB	Seres Therapeutics, Inc.	1,940	-0.39	-0.33	-0.28	Seres Therapeutics EPS misses by $0.08, misses on revenue [5/4/2021 7:07 AM]	21.48	1.13 (5.55%)	21.48	0.0 (0.00%)	3.41 - 38.50	1,261,937	550,000	6,432
Seres Therapeutics EPS misses by $0.08, misses on revenue [5/4/2021 7:07 AM] Seres Therapeutics, Inc. to Host Earnings Call [May-04-21 06:45AM] Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates [May-04-21 07:00AM] Seres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue Estimates [May-04-21 08:20AM]
02-03-2021	PM	7:00 AM ET (Mar 2)	MCRB	Seres Therapeutics, Inc.	1,740	-0.18	-0.26	-0.25	Seres Therapeutics EPS misses by $0.02, beats on revenue [3/2/2021 7:11 AM]	19.73	-0.89 (-4.32%)	20.70	0.08 (0.39%)	2.52 - 38.50	894,982	1,076,707	10,207
Seres Therapeutics EPS misses by $0.02, beats on revenue [3/2/2021 7:11 AM] Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates [Mar-02-21 07:00AM] Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis [Mar-02-21 07:00AM] Seres Therapeutics, Inc. to Host Earnings Call [Mar-02-21 06:30AM]
09-11-2020	PM	7:00 AM ET (Nov 9)	MCRB	Seres Therapeutics, Inc.	3,140	-0.36	-0.24	-0.23	Seres Therapeutics EPS misses by $0.10, misses on revenue [11/9/2020 7:03 AM]	33.22	-1.37 (-3.96%)	34.00	-0.59 (-1.71%)	2.52 - 36.00	654,391	563,502	1,565